Multi-centre, Open-label, Single Arm, Phase I Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacogenomics and Efficacy of a Single Intravenous Dose of BI 655130 in Patients With Active Generalized Pustular Psoriasis.
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 10 Nov 2017
At a glance
- Drugs BI 655130 (Primary)
- Indications Pustular psoriasis
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 06 Nov 2017 Status changed from recruiting to active, no longer recruiting.
- 02 Oct 2017 Planned End Date changed from 17 Feb 2018 to 19 Mar 2018.
- 02 Oct 2017 Planned primary completion date changed from 28 Oct 2017 to 27 Nov 2017.